Michael Polansky has a new, skin-focused biotech. Don’t call it a drug company.
Though its data could be useful for pharmaceutical firms, Polansky’s latest entrepreneurial endeavor, Outer Bio, is serious about steering clear of road bumps that slow biotechs.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.